Trial Profile

A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MHB-036C (Primary)
Indications HER2 negative breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Minghui Pharmaceutical (Shanghai)

Most Recent Events

20 May 2025 According to Minghui Pharmaceutical media release, dose-escalation study phase I portion of MHB039A trial has been completed.
04 Jun 2024 Results (At data cutoff (Dec 31, 2023), n=26) assessing safety and efficacy of MHB036C in locally advanced or metastatic solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
22 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com